JAZZ - Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug
On Wednesday, Jazz Pharmaceuticals' (NASDAQ: JAZZ) Xywav won Food and Drug Administration approval as a treatment for people with narcolepsy. The drug has been found to reduce cataplexy -- a sudden loss of muscle tone -- and excessive daytime sleepiness associated with the condition.
The approval is important because Xywav was formulated to contain 92% less sodium than Jazz Pharmaceuticals' older narcolepsy treatment, Xyrem -- the current standard of care in this indication. A low-sodium diet is recommended by the American Heart Association because high-sodium diets can contribute to cardiovascular disease.
IMAGE SOURCE: GETTY IMAGES.